Movado agrees to sell 95% stake in EBEL to Montres Journe-led group for $66.5 million
Bitget2026/10/08 10:45Movado agreed to sell a 95% stake in its EBEL brand for $66.5 million to a buyer group led by Montres Journe. Chanel is participating in the buyer group; Movado will retain a 5% interest in the business. Pierre Jacques is set to become EBEL chief executive following closing, which is expected in the next few months. The deal transfers EBEL-related trademarks, inventory, and other assets, including the Villa Turque, into a new Swiss subsidiary. Movado plans to provide transition services to support continuity for EBEL’s customers and business partners. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Movado Group Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080645BIZWIRE_USPR_____20261007_BW179505) on October 08, 2026, and is solely responsible for the information contained therein.
- Movado agreed to sell a 95% stake in its EBEL brand for $66.5 million to a buyer group led by Montres Journe.
- Chanel is participating in the buyer group; Movado will retain a 5% interest in the business.
- Pierre Jacques is set to become EBEL chief executive following closing, which is expected in the next few months.
- The deal transfers EBEL-related trademarks, inventory, and other assets, including the Villa Turque, into a new Swiss subsidiary.
- Movado plans to provide transition services to support continuity for EBEL’s customers and business partners.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
